The malaria epidemiological situation in Armenia has begun deteriorating since 1994 when the increased importation of vivax malaria made the previously endemic foci of malaria to function. In 1998, the maximum cases (n = 1156) were notified; of them, there were 542 cases of local origin. The main vectors of malaria in Armenia were An. maculipennis, An. sacharovi, An. claviger, An. hyrcanus, An. superpictus, An. plumbeus. By applying the main provisions of the WHO "Roll Back Malaria" strategy, the Ministry of Health of Armenia has implemented a package of antiepidemic measures that could substantially reduce the incidence of the disease and create real prerequisites for malaria eradication.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Frequency and Incidence of QT Prolongation with Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country MDR/RR-TB Cohort.
Clin Infect Dis
December 2024
Interactive Research & Development (IRD) Global, Singapore, Singapore.
Background: The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen and six months or longer for Bdq and delamanid (Dlm) in the 18-20-month longer regimen. However, lack of evidence on extended treatment using Bdq or Dlm has limited their use to six months. We examine the frequency and incidence of QT prolongation based on duration of Bdq and/or Dlm use in longer regimens.
View Article and Find Full Text PDFEvaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study.
Biomedicines
September 2024
Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé P.O. Box 1364, Cameroon.
Article Synopsis
- Mortality in children accounts for 15% of global AIDS-related deaths, with Cameroon facing a higher rate of 25%, mainly due to poor viral response.
- A study analyzed viral suppression (VS) among Cameroonian children and young adults receiving antiretroviral therapy (ART) to identify factors affecting VS, finding an overall rate of 82.3%.
- Key findings revealed that younger age, longer ART duration, and certain non-DTG-based regimens were independent predictors of non-VS, suggesting the need for prioritizing transition to DTG-based regimens to improve outcomes.
Optimising HIV spending in 12 eastern European and central Asian countries: a modelling study.
Lancet HIV
October 2024
Burnet Institute, Melbourne, VIC, Australia.
Background: The eastern European and central Asian (EECA) region has the fastest growing HIV epidemic globally. We aimed to identify how HIV resources could be allocated for maximum health impact.
Methods: Between Aug 1 and Dec 23, 2022, allocative efficiency analyses were undertaken for 12 countries in the EECA region (Albania, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kosovo, Kyrgyzstan, Moldova, Serbia, Tajikistan, and Uzbekistan) using HIV epidemic models developed with Optima HIV.
Primaquine-induced hemolysis in a Colombian patient with glucose-6-phosphate dehydrogenase deficiency.
Travel Med Infect Dis
September 2024
Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá, D.C., Colombia; Servicio de Infectología, Hospital Militar Central, Bogotá, D.C., Colombia; Servicios y Asesorías en Infectología - SAI, Bogotá, D.C., Colombia. Electronic address:
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Lancet Infect Dis
October 2024
Division of Communicable Diseases, Environment, and Health, WHO Regional Office for Europe, Copenhagen, Denmark.
Background: In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine for the management of rifampicin-resistant tuberculosis. A high prevalence of resistance to constituent drugs precluded its widespread use by countries in the WHO European region. We evaluated three 9-month fully oral modified STRs (mSTRs) in which ethionamide, ethambutol, isoniazid, and pyrazinamide were replaced by linezolid, cycloserine, or delamanid (or a combination).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!